An Amsterdam UMC-based biotech spin-off, which focuses on developing vaccine-based cancer immunotherapy
CimCure has raised €5.0M across 1 funding round from 2 investors, most recently a Seed round in Jun 2022. Based in Amsterdam, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-07 | Seed | €5.0M |
| Positron Ventures,Tom Würdinger |
| View deal → |
